Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Intractable 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cancer Pain 1

Interventions

resiniferatoxin 1cannabichromene 1Transcutaneous Electric Nerve Stimulation 1Transcranial Direct Current Stimulation 1Tramadol 1Therapeutic Touch 1Telemedicine 1Surveys and Questionnaires 1Standard of Care 1Spinal Cord Stimulation 1Radiosurgery 1Pharmacogenomic Testing 1Patient Education as Topic 1Pain Management 1Oxycodone 1Midazolam 1Massage 1Lidocaine 1Laser Therapy 1Electroacupuncture 1Duloxetine Hydrochloride 1Dronabinol 1Control Groups 1Cognitive Behavioral Therapy 1Cannabidiol 1Art Therapy 1Acupuncture Therapy 1Acupressure 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cancer Pain × resiniferatoxin × 1 year × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡